Gladstone spinout Tenaya tackles new cures for heart failure with $50M A round
The idea that a fresh source of regenerative cells could repair a damaged heart has driven a variety of largely unsuccessful research efforts aimed at helping patients who have suffered from heart attacks and strokes. But now The Column Group is bankrolling a $50 million Series A for an upstart biotech that hopes to do just that.
The biotech is called Tenaya Therapeutics, the brainchild in part of Deepak Srivastava, MD, director of the San Francisco-based Gladstone Institute of Cardiovascular Disease and a co-founder of the new company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
